# CMMB catalysts: Chemomab Therapeutics Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cmmb/catalysts

> Chemomab Therapeutics Ltd. (CMMB) has 3 upcoming catalysts. The next is the chemomab topline data readout, 1H 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CMMB?

Chemomab Therapeutics Ltd. (CMMB) has 3 upcoming catalysts. The next is the chemomab topline data readout, 1H 2028. Press release filed with the SEC (EX-99): "A topline readout of the RA Phase 2 trial results is expected in H1 2028." [Calendar and source filings](https://sec-api.dev/companies/cmmb/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001178913-26-003442, https://www.sec.gov/Archives/edgar/data/1534248/000117891326003442/exhibit_99-1.htm (retrieved 2026-11-12). Last confirmed 2026-07-08. Cite: https://sec-api.dev/companies/cmmb/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Chemomab Therapeutics Ltd. |
| Ticker | CMMB (Nasdaq) |
| SEC CIK | 1534248 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cmmb |

## Cash runway

Cash $7.6M as of 2025-12-31; quarterly burn $2.8M; about 8.2 months of runway at that rate (XBRL company facts, accession 0001178913-26-001593).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2024 | [Nebokitug topline data readout](https://sec-api.dev/pdufa/nebokitug) | CMMB |  | completed, positive | "Positive topline results from the double-blinded portion of this trial were reported in July 2024 and results from the open label part were reported in March 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534248/000117891325002894/exhibit_99-2.htm)) |
| July 25, 2024 | [Chemomab topline data readout](https://sec-api.dev/pdufa/chemomab) | CMMB |  | completed, positive | "On July 25, 2024, Chemomab reported positive topline results from the nebokitug Phase 2 SPRING trial in patients with PSC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534248/000117891325000658/exhibit_99-1.htm)) |
| Mar 2025 | [Nebokitug topline data readout](https://sec-api.dev/pdufa/nebokitug) | CMMB |  | completed, positive | "Positive topline results from the double-blinded portion of this trial were reported in July, 2024 and results from the open label part were reported in March 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1534248/000117891326001593/zk2634510.htm)) |
| 1H 2028 | [Chemomab topline data readout](https://sec-api.dev/pdufa/chemomab) | CMMB |  | scheduled | "A topline readout of the RA Phase 2 trial results is expected in H1 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534248/000117891326003442/exhibit_99-1.htm)) |
| 1H 2028 | [Nebokitug topline data readout](https://sec-api.dev/pdufa/nebokitug) | CMMB | rheumatoid arthritis, with topline results | scheduled | "The combined company plans to initially focus on advancing nebokitug, a first-in-class clinical-stage anti-CCL24 antibody, into a Phase 2 clinical trial for the treatment of rheumatoid arthritis, with topline results expected in the first half of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534248/000117891326004193/exhibit_99-2.htm)) |
| June 2028 | [Chemomab Therapeutics Ltd. primary completion](https://sec-api.dev/companies/cmmb/catalysts) | CMMB | Systemic Sclerosis | delayed | "NCT06210945 (Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis): Overall Status SUSPENDED; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor ChemomAb Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06210945)) |

## Drugs

- [Chemomab](https://sec-api.dev/pdufa/chemomab): 
- [Nebokitug](https://sec-api.dev/pdufa/nebokitug): rheumatoid arthritis, with topline results

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cmmb/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CMMB catalysts: Chemomab Therapeutics Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cmmb/catalysts

```bibtex
@misc{secapidev_companies_cmmb_catalysts_20261116,
  title        = {CMMB catalysts: Chemomab Therapeutics Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cmmb/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cmmb_catalysts_20261116","title":"CMMB catalysts: Chemomab Therapeutics Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cmmb/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
